Study to Evaluate the Effects of Neramexane on the Pharmacokinetics of a Combined Drospirenone/Ethinyl Estradiol Oral Contraceptive in Healthy Female Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions

Healthy

Interventions

DRUG

Neramexane

25 mg q.d., 3 days 2 x 25 mg b.i.d., 11 days

Trial Locations (1)

AAIharma Deutschland GmbH & Co. KG, Neu-Ulm